December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nautilus Biotechnology, Inc. - Common Stock (NQ:NAUT)

2.650 +0.240 (+9.96%)
Streaming Delayed Price Updated: 2:56 PM EST, Mar 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nautilus Biotechnology, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
Veteran sales leader with proven proteomics and life sciences track record from Olink and SomaLogic joins Nautilus to accelerate commercial progress of its Voyager Platform 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with the potential to accelerate Alzheimer’s and... 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Third Quarter 2025 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free
Via ACCESS Newswire
News headline image
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Second Quarter 2025 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports First Quarter 2025 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce First Quarter 2025 Financial Results on April 29, 2025
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the TD Cowen 45th Annual Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator Award
Dr. Mallick to be inducted into the Academy for Radiology and Biomedical Imaging Research’s esteemed Council of Distinguished Investigators for his outstanding contributions to medical imaging 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Third Quarter 2024 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Third Quarter 2024 Financial Results on October 29, 2024
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Appoints Mass Spectrometry Leader Ken Suzuki as Chief Marketing Officer
Industry veteran brings multidisciplinary expertise leading Mass Spectrometry division at Agilent Technologies to a company building a platform to power next-generation proteomics 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Reports Second Quarter 2024 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.